433 related articles for article (PubMed ID: 34534464)
1. Antigen dominance hierarchies shape TCF1
Burger ML; Cruz AM; Crossland GE; Gaglia G; Ritch CC; Blatt SE; Bhutkar A; Canner D; Kienka T; Tavana SZ; Barandiaran AL; Garmilla A; Schenkel JM; Hillman M; de Los Rios Kobara I; Li A; Jaeger AM; Hwang WL; Westcott PMK; Manos MP; Holovatska MM; Hodi FS; Regev A; Santagata S; Jacks T
Cell; 2021 Sep; 184(19):4996-5014.e26. PubMed ID: 34534464
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
3. TCF1
Koh J; Kim S; Woo YD; Song SG; Yim J; Han B; Lim S; Ahn HK; Mun S; Kim JS; Keam B; Kim YA; Lee SH; Jeon YK; Chung DH
Eur J Cancer; 2022 Oct; 174():10-20. PubMed ID: 35970031
[TBL] [Abstract][Full Text] [Related]
4. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
5. Tumor immunogenicity dictates reliance on TCF1 in CD8
Escobar G; Tooley K; Oliveras JP; Huang L; Cheng H; Bookstaver ML; Edwards C; Froimchuk E; Xue C; Mangani D; Krishnan RK; Hazel N; Rutigliani C; Jewell CM; Biasco L; Anderson AC
Cancer Cell; 2023 Sep; 41(9):1662-1679.e7. PubMed ID: 37625402
[TBL] [Abstract][Full Text] [Related]
6. Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.
Li S; Simoni Y; Zhuang S; Gabel A; Ma S; Chee J; Islas L; Cessna A; Creaney J; Bradley RK; Redwood A; Robinson BW; Newell EW
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34285073
[TBL] [Abstract][Full Text] [Related]
7. Intravenous nanoparticle vaccination generates stem-like TCF1
Baharom F; Ramirez-Valdez RA; Tobin KKS; Yamane H; Dutertre CA; Khalilnezhad A; Reynoso GV; Coble VL; Lynn GM; Mulè MP; Martins AJ; Finnigan JP; Zhang XM; Hamerman JA; Bhardwaj N; Tsang JS; Hickman HD; Ginhoux F; Ishizuka AS; Seder RA
Nat Immunol; 2021 Jan; 22(1):41-52. PubMed ID: 33139915
[TBL] [Abstract][Full Text] [Related]
8. PGE
Lacher SB; Dörr J; de Almeida GP; Hönninger J; Bayerl F; Hirschberger A; Pedde AM; Meiser P; Ramsauer L; Rudolph TJ; Spranger N; Morotti M; Grimm AJ; Jarosch S; Oner A; Gregor L; Lesch S; Michaelides S; Fertig L; Briukhovetska D; Majed L; Stock S; Busch DH; Buchholz VR; Knolle PA; Zehn D; Dangaj Laniti D; Kobold S; Böttcher JP
Nature; 2024 May; 629(8011):417-425. PubMed ID: 38658748
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
Caushi JX; Zhang J; Ji Z; Vaghasia A; Zhang B; Hsiue EH; Mog BJ; Hou W; Justesen S; Blosser R; Tam A; Anagnostou V; Cottrell TR; Guo H; Chan HY; Singh D; Thapa S; Dykema AG; Burman P; Choudhury B; Aparicio L; Cheung LS; Lanis M; Belcaid Z; El Asmar M; Illei PB; Wang R; Meyers J; Schuebel K; Gupta A; Skaist A; Wheelan S; Naidoo J; Marrone KA; Brock M; Ha J; Bush EL; Park BJ; Bott M; Jones DR; Reuss JE; Velculescu VE; Chaft JE; Kinzler KW; Zhou S; Vogelstein B; Taube JM; Hellmann MD; Brahmer JR; Merghoub T; Forde PM; Yegnasubramanian S; Ji H; Pardoll DM; Smith KN
Nature; 2021 Aug; 596(7870):126-132. PubMed ID: 34290408
[TBL] [Abstract][Full Text] [Related]
11. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
[TBL] [Abstract][Full Text] [Related]
12. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
13. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Anagnostou V; Smith KN; Forde PM; Niknafs N; Bhattacharya R; White J; Zhang T; Adleff V; Phallen J; Wali N; Hruban C; Guthrie VB; Rodgers K; Naidoo J; Kang H; Sharfman W; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Zahnow CA; Baylin SB; Scharpf RB; Brahmer JR; Karchin R; Pardoll DM; Velculescu VE
Cancer Discov; 2017 Mar; 7(3):264-276. PubMed ID: 28031159
[TBL] [Abstract][Full Text] [Related]
14. Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses.
Santos PM; Adamik J; Howes TR; Du S; Vujanovic L; Warren S; Gambotto A; Kirkwood JM; Butterfield LH
J Exp Med; 2020 Jul; 217(7):. PubMed ID: 32369107
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade-unresponsive human tumor-infiltrating CD8
Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
[TBL] [Abstract][Full Text] [Related]
16. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
17. Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T; Mitsuhashi A; Ogino H; Saijo A; Otsuka K; Yoneda H; Tobiume M; Nguyen NT; Goto H; Koyama K; Sugimoto M; Kondoh O; Nokihara H; Nishioka Y
J Immunol; 2021 Mar; 206(6):1204-1214. PubMed ID: 33504617
[TBL] [Abstract][Full Text] [Related]
18. Functional HPV-specific PD-1
Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral-based vaccine promotes neoantigen-specific CD8
D'Alise AM; Brasu N; De Intinis C; Leoni G; Russo V; Langone F; Baev D; Micarelli E; Petiti L; Picelli S; Fakih M; Le DT; Overman MJ; Shields AF; Pedersen KS; Shah MA; Mukherjee S; Faivre T; Delaite P; Scarselli E; Pace L
Sci Transl Med; 2022 Aug; 14(657):eabo7604. PubMed ID: 35947675
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8
Fehlings M; Simoni Y; Penny HL; Becht E; Loh CY; Gubin MM; Ward JP; Wong SC; Schreiber RD; Newell EW
Nat Commun; 2017 Sep; 8(1):562. PubMed ID: 28916749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
